The European Medicines Agency published guideline E11A on pediatric extrapolation adopted by the International Council for Harmonisation (ICH) Assembly. The guideline: ➡ Ensures that pediatric populations participate in trials only when necessary ➡ Refines the pediatric extrapolation framework ➡ Reduces the likelihood of substantial differences between regions https://hubs.li/Q02NFCl50 #GlobalHealth #clinicalresearch #clinicaltrials
Veristat’s Post
More Relevant Posts
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Palforzia, defatted powder of Arachis hypogaea L., semen (peanuts), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0103/2023
EMEA-001734-PIP01-14-M06 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0469/2020
EMEA-000715-PIP03-11-M06 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Beyfortus, Nirsevimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0296/2021
EMEA-001784-PIP01-15-M04 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Benlysta, belimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0395/2022
EMEA-000520-PIP02-13-M04 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0295/2023
EMEA-001397-PIP04-17-M02 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Vimizim, Recombinant human N-acetylgalactosamine-6-sulfatase (elosulfase alfa), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0170/2023
EMEA-000973-PIP01-10-M04 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Onglyza, Saxagliptin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0478/2022
EMEA-000200-PIP01-08-M10 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Tavneos, Avacopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0352/2023
EMEA-002023-PIP01-16-M07 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0308/2023
EMEA-000576-PIP01-09-M15 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
-
PN Update: Opinion/decision on a Paediatric investigation plan (PIP): Leqvio, Inclisiran sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0322/2023
EMEA-002214-PIP01-17-M02 - paediatric investigation plan | European Medicines Agency (EMA)
ema.europa.eu
